Publications by authors named "Ari Joseph Rosenberg"
Article Synopsis
- The study investigates the effectiveness of enfortumab vedotin (EV), an antibody-drug conjugate targeting nectin-4, in patients with unresectable recurrent/metastatic head and neck cancer (HNC) who have previously received other therapies.
- In a phase II trial involving 46 patients, the objective response rate (ORR) was 23.9%, with a disease control rate (DCR) of 56.5%, while median progression-free survival (PFS) and overall survival (OS) were 3.9 and 6.0 months, respectively.
- Adverse events were primarily alopecia, fatigue, and peripheral sensory neuropathy, with 34.8% of patients experiencing
Lessons Learned: Adding docetaxel to the modified FOLFOX7 backbone (DOF) is a feasible three-drug combination therapy for advanced gastric cancer with high activity, providing evidence that leucovorin is not necessary in this setting.The DOF regimen represents an alternative to the FLOT (5-FU 2,600 mg/m as 24-hour infusion with leucovorin 200 mg/m, oxaliplatin 85 mg/m, and docetaxel 50 mg/m) regimen that can be considered in select patients with advanced gastric cancer and is a potential choice in the curative setting.
Background: The combination of docetaxel, cisplatin, and 5-fluorouracil (5-FU) demonstrates high response rates in advanced gastric cancer, albeit with increased toxicity.